Orthopediatrics Corp ((KIDS)) has held its Q4 earnings call. Read on for the main highlights of the call.
OrthoPediatrics Corp Reports Strong Growth and Record Patient Impact in 2024
OrthoPediatrics Corp’s latest earnings call revealed a positive sentiment, highlighting the company’s strong growth trajectory and record patient impact in 2024. Despite facing challenges with international sales and a decline in gross margins due to expense reclassifications, the company remains optimistic about its future growth prospects. Strategic restructuring efforts and new product launches are expected to drive long-term profitability.
Record-High Patient Impact
In 2024, OrthoPediatrics achieved a significant milestone by helping over 138,000 children, marking a record high for the company. This achievement underscores the company’s commitment to expanding its impact and improving patient outcomes.
Revenue and Growth Metrics
OrthoPediatrics reported a total revenue of $52.7 million for Q4 2024, representing a 40% increase from the previous year. The company projects full-year revenue for 2025 to be between $235 to $242 million, indicating an annual growth of 15% to 18%.
Significant Growth in Key Segments
The company’s TMD and scoliosis segments experienced substantial growth, with quarterly increases of 35% and 62%, respectively. The global revenue for scoliosis alone rose by 62% compared to the prior year, showcasing the company’s strong performance in these areas.
Adjusted EBITDA Improvement
OrthoPediatrics saw its adjusted EBITDA more than double in Q4 2024 to $3.0 million. The company expects adjusted EBITDA for 2025 to be between $15 to $17 million, reflecting its focus on improving operational efficiency.
Positive Free Cash Flow Projection
The company anticipates achieving its first quarter of positive free cash flow by Q4 2025, marking a significant financial milestone and demonstrating its commitment to financial sustainability.
Expansion and Integration Success
OrthoPediatrics successfully integrated Boston OMP and expanded its OPSB business, with plans to enter four new territories in 2025. This expansion is expected to enhance the company’s market presence and drive future growth.
Strong International Demand
Despite challenges, the EMEA T&D growth remained robust due to high demand, with non-LATAM T&D growth exceeding 20% and scoliosis growing nearly 30%. This indicates strong international interest in the company’s offerings.
New Product Launches and R&D Advancements
The company launched several new products, including the PMP Tibia and DF2 femur fracture brace, and plans to beta launch the 3P hip system and new EOS products, highlighting its commitment to innovation and product development.
Slower International Sales
International revenue growth was limited to 5% due to a strategic decision to reduce set sales shipments to South America, particularly Brazil, in response to currency fluctuations.
Gross Margin Decline
OrthoPediatrics reported a gross profit margin of 68% for Q4 2024, down from 71% in the previous year, primarily due to expense reclassifications within OPSB.
One-Time Charges and Restructuring
The company incurred a $3.7 million restructuring charge related to the closure of its OP Israel office and the relocation of production to the US, reflecting its strategic focus on optimizing operations.
Flat Guidance for Gross Margins
OrthoPediatrics provided flat guidance for gross margins, maintaining them at 72% to 73%, indicating that cost reclassifications will not impact overall profitability.
Forward-Looking Guidance
Looking ahead, OrthoPediatrics expects to achieve full-year 2025 revenue between $235 to $242 million, with adjusted EBITDA projected between $15 to $17 million. The company also anticipates its first quarter of positive free cash flow by the end of 2025, signaling a strong financial outlook.
In summary, OrthoPediatrics Corp’s earnings call reflected a positive sentiment, with the company achieving record patient impact and significant revenue growth. Despite some challenges, the company’s strategic initiatives and new product launches position it well for continued success and long-term profitability.